You are using an outdated browser. We suggest you update your browser for a better experience. Click here for update.
Close this notification.
Skip to main content Skip to search

 

877 Results
Regimen
Cancer Type:
Breast, 
Central Nervous System, 
Endocrine, 
Gastrointestinal, 
Genitourinary, 
Gynecologic, 
Head and Neck, 
Hematologic, 
Lung, 
Sarcoma, 
Skin, 
Unknown Primary
Intent: Supportive Care, Palliative
Jan 2018
Regimen
Cancer Type:
Hematologic, 
Multiple Myeloma
Intent: Palliative
Funding:
ODB - General Benefit
    cyclophosphamide - oral tablets
New Drug Funding Program
    Bortezomib - Previously Untreated - Multiple Myeloma
ODB - General Benefit
    dexamethasone
New Drug Funding Program
    Daratumumab in Combination with a Bortezomib-Based Regimen for Newly Diagnosed Transplant Ineligible Multiple Myeloma
Sep 2022
Regimen
Cancer Type:
Hematologic, 
Multiple Myeloma
Intent: Palliative
Funding:
New Drug Funding Program
    Bortezomib - Previously Untreated - Multiple Myeloma Pre-Stem Cell Transplant
ODB - General Benefit
    dexamethasone
Apr 2025
Regimen
Cancer Type:
Hematologic, 
Multiple Myeloma
Intent: Palliative
Funding:
New Drug Funding Program
    Bortezomib - Previously Untreated - Multiple Myeloma Pre-Stem Cell Transplant
ODB - General Benefit
    dexamethasone
Sep 2025
Regimen
Cancer Type:
Hematologic, 
Multiple Myeloma
Intent: Palliative
Funding:
ODB - General Benefit
    dexamethasone
Sep 2019
Regimen
Cancer Type:
Gynecologic, 
Endometrial
Intent: Adjuvant, Palliative
Aug 2021
Regimen
Cancer Type:
Gynecologic, 
Endometrial
Intent: Palliative
May 2020
Regimen
Cancer Type:
Genitourinary, 
Testis
Intent: Palliative
May 2019
Regimen
Cancer Type:
Skin, 
Merkel Cell
Intent: Palliative
Oct 2017
Regimen
Cancer Type:
Gastrointestinal, 
Pancreas
Intent: Palliative
Funding:
ODB - General Benefit
    capecitabine
Apr 2023
Regimen
Cancer Type:
Endocrine, 
Adrenal
Intent: Palliative
Funding:
ODB - General Benefit
    capecitabine
Apr 2023
Regimen
Cancer Type:
Lung, 
Mesothelioma (Pleural)
Intent: Palliative
Funding:
New Drug Funding Program
    Raltitrexed - Advanced Malignant Pleural Mesothelioma (MPM)
May 2019

Pages